Long-term safety and efficacy of trospium chloride for the treatment of neurogenic overactive bladder due to Parkinson's disease - is there an effect on cognitive status?

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Aim. To evaluate the efficiency of long-term use of trospium chloride (Spazmex) for the treatment of patients with neurogenic overactive bladder due to Parkinson's disease (PD) and to determine the influence of therapy on the cognitive status of patients. Materials and methods: 60 patients with PD and neurogenic overactive bladder with stages 2.5, 3 and 4 according to Hoehn-Yahr scale were included in the main group. The mean age was 58.2±5.7 years. All patients were prescribed trospium chloride at entry into the study, with doses titrated gradually according to clinical efficacy (30 to 90 mg). The comparison group included 15 patients with PD and neurogenic overactive bladder at stages 2,5 and 3, who received tibial neuromodulation according to the standard technique with skin electrodes. The mean age of patients was 56.4±4.6 years. At baseline, both groups were comparable in terms ofgender, age and cognitive status (p=0.801). All patients received treatment for 52 weeks. The efficiency of therapy was assessed according to bladder diaries, while safety outcomes included postvoid residual, side effects, cognitive status according to the MoCA scale and quality of life according to the SF-Qualiveen questionnaire. Results: clinical efficacy and satisfaction were achieved in all patients who completed the study (47 patients in the main group and 15 patients in the comparison group). Good clinical efficacy was demonstrated in both groups, since there was a decrease in the number of urinations, episodes of urgency and urinary incontinence. In addition, there was an improvement in the quality of life according to the SF-Qualiveen scale. The cognitive status during the entire follow-up period remained without significant changes in both groups. Conclusion. Trospium chloride is an effective drug in patients with PD. It does not affect cognitive functions during long-term use. Trospium chloride should be considered as first-line drug in those with urologic manifestations of PD.

Full Text

Restricted Access

About the authors

E. S Korshunova

FGBNU Research Center of Neurology; FGBU “Central state medical academy” of Administrative Directorate of the President of Russian Federation; A.I. Evdokimov’s Moscow State University of Medicine and Dentistry

Email: e_korshunova@mail.ru
Ph.D., associate professor Moscow, Russia; Moscow, Russia

M. N Andreev

FGBNU Research Center of Neurology; M.V. Lomonosov’s Moscow State University

neurologist; Ph.D. student of the Faculty of Fundamental Medicine Moscow, Russia

M. N Korshunov

FGBU “Central state medical academy” of Administrative Directorate of the President of Russian Federation

PhD, associate professor Moscow, Russia

T. M Pyatnitskaya

M.V. Lomonosov’s Moscow State University

Email: tomapyatnitskaya@gmail.com
student Moscow, Russia

D. M Korshunov

A.I. Evdokimov’s Moscow State University of Medicine and Dentistry

student Moscow, Russia

S. P Darenkov

FGBU “Central state medical academy” of Administrative Directorate of the President of Russian Federation

Ph.D., MD, Professor, Head of the Department of Urology Moscow, Russia

N. A Suponeva

FGBNU Research Center of Neurology

Ph.D., MD, Professor, Corresponding member of Russian Academy of Sciences, Director of the Institute of Neurorehabilitation Moscow, Russia


  1. https://www.who.int/ru/news-room/fact-sheets/detail/parkinson-disease
  2. Sakakibara R., Panicker J., Finazzi-Agro E., Iacovelli V., & Bruschini H.(2015). A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourology and Urodynamics, 35(5), 551-563. doi: 10.1002/nau.22764.
  3. Мазуренко Е.В., Пономарев В.В., Сакович Р.А. Когнитивные нарушения при болезни Паркинсона. Медицинские новости. 2014;1:6-11.
  4. https://cr.minzdrav.gov.ru/recomend/588_2
  5. Bell B., Avery A., Bishara D., Coupland C., Ashcroft D., Orrell M. Anticholinergic drugs and risk of dementia: Time for action? Pharmacol Res Perspect. 2021;9(3):e00793. doi: 10.1002/prp2.793. PMID: 34087056; PMCID: PMC8177062.
  6. https://www.rlsnet.ru
  7. Alka A. Bhide,Visha Tailor, Ruwan Fernando, Vik Khullar, Giuseppe Alessandro Digesu. Posteriortibial nerve stimulation for overactive bladder -techniques and efficacy.Int Urogynecol J. 2020;31(5):865-870. doi: 10.1007/s00192-019-04186-3
  8. Филиппова Е.С., Баженов И.В., Зырянов А.В., Борзунов И.В., Москвина Е.Ю., Морозова А.А., Буксман А.И. Оценка качества жизни, связанного с нарушениями мочеиспускания, у больных рассеянным склерозом: перевод и валидизация русскоязычной версии опросника SF-Qualiveen. Уральский медицинский журнал. 2019;3:39-43. https://doi.org/10.25694/URMJ.2019.03.19
  9. Ziad S. Nasreddine, Natalie A. Phillips, Valerie Bedirian, Simon Charbonneau, Victor Whitehead.The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatrics Soc. 2005;53(4):695-699. doi: 10.1111/j.1532-5415.2005.53221.x
  10. Herschorn S., Stothers L., Carlson K., Egerdie B., Gajewski J.B., Pommerville P., Schulz J., Radomski S., Drutz H., Barkin J, Paradiso-Hardy F. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol. 2010;183(5):1892-1898. doi: 10.1016/j.juro.2010.01.012.
  11. Guay D.R.P. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42:1243-1285. doi: 10.2165/00003088-200342140-00004
  12. Ohtake A., Saitoh C., Yuyama H. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull.2007;30:54-58. doi: 10.1248/bpb.30.54.
  13. Chapple C.R., Khullar V., Gabriel Z. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543-562. doi: 10.1016/j.eururo.2008.06.047
  14. Ortiz de Montellano, Paul R. Cytochrome P450: structure, mechanism, and biochemistry. 3rd edition. New York: Kluwer Academic/Plenum Publishers, 2005. ISBN 0-306-48324-6
  15. Callegari E., Malhotra B., Bungay P.J., Webster R., Fenner K.S., Kempshall S., LaPerle J.L., Michel M.C., Kay G. A comprehensive non-clinical evaluation of the CNS pene.tration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72(2):235-246. doi: 10.1111/j.1365-2125.2011.03961.x.
  16. Коршунова Е.С., Коршунов М.Н. Гиперактивный мочевой пузырь у мольтиморбидных больных. Что нужно помнить? Consilium Medicum. 2018;20(7):41-45). doi: 10.26442/2075-1753_2018.7.41-45.
  17. Gray S.L., et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401. doi: 10.1001/jamainternmed.2014.7663
  18. Risacher S.L., et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurology, 2016.73:721. doi: 10.1001/jamaneurol.2016.0580.
  19. Jumadilova Z., et al. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin. Am J Health Syst Pharm, 2006;63:2357. doi: 10.2146/ajhp060038
  20. Staskin D, Kay G, Tannenbaum C, Goldman HB, Bhashi K, Ling J, Oefelein MG.Trospium Chloride Has No Effect on Memory Testing and Is Assay Undetectable in the Central Nervous System of Older Patients with Overactive Bladder.Int J Clin Pract 2010;64:1294-300. doi: 10.1111/j.1742-1241.2010.02433.x
  21. Araklitis G, Robinson D, Cardozo L. Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder. Clinical Interventions in Aging. 2020;15:1493-1503. doi: 10.2147/CIA.S252852
  22. Ivchenko A., Bödeker RH., Neumeister C. et al. Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective noninterventional study. BMC Urol 2018; 18:80. doi.org/10.1186/s12894-018-0394-8
  23. Anthony G. Visco, Linda Brubaker, Holly E. Richter, Ingrid Nygaard, Marie Fidela R. Paraiso, Shawn A. Menefee, Joseph Schaffer, Jerry Lowder, Salil Khandwala, Larry Sirls, Cathie Spino, Tracy L. Nolen, Dennis Wallace, Susan F. Meikle. Anticholinergic Therapy vs. Onabotulinumtoxin A for Urgency Urinary Incontinence. N Engl J Med. 2012;367(19):1803-13. doi: 10.1056/NEJMoa1208872.
  24. Non-dopamine Lesions in Parkinson’s Disease. Ed. G Halliday, R Barker, D Rowe. Oxford University Press; 2011, Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson’s disease. Mov Disord. 2008;23:1065-1075

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies